Researchers to Develop Vaccines, Therapies for Nipah and Hendra Viruses

The Uniformed Services University of the Health Sciences (USU), along with Profectus Biosciences, Inc., the Vanderbilt University Medical Center, Mapp Biopharmaceutical, Inc., and the University of Texas Medical Branch (UTMB), have been awarded up to $24.5 million to advance treatments for the highly lethal henipaviruses, Nipah and Hendra.

Content Information

Content Author: 

Content Source: 
Infection Control Today

Content Type: